Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07128381 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
A Phase 1 study of Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML), sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
- 1
- Study location
NCT07128381 is a Phase 1 study of Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 66 participants, below the 975-participant average among 6 other Myelofibrosis (MF) trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07128381, a Phase 1 study of Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML), is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
- 1
- Study location
Study Summary
* To find the recommended dose of axatilimab given alone and in combination with ruxolitinib in patients with MF and CMML. * To learn if axatilimab given in combination with ruxolitinib can help to control MF and CMML.
Conditions Studied
Interventions
- DRUG Ruxolitinib
- DRUG Axatilimab (SNDX-6352)
Study Locations (1)
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2026-01-02 |
| Est. Completion | 2033-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07128381
The ClinicalTrials.gov registry entry for NCT07128381 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 975-participant average among 6 other Myelofibrosis (MF) trials with a reported enrollment target (93% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Myelofibrosis (MF) appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT07128381 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07128381 about?
NCT07128381 is a clinical study titled "Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)". * To find the recommended dose of axatilimab given alone and in combination with ruxolitinib in patients with MF and CMML. * To learn if axatilimab given in combination with ruxolitinib can help to control MF and CMML.
What is the current status of trial NCT07128381?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2026-01-02. Estimated completion is 2033-07-31.
What conditions does trial NCT07128381 study?
This clinical trial studies the following conditions: Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML).
What interventions are being tested in trial NCT07128381?
The interventions under investigation include: Ruxolitinib (DRUG), Axatilimab (SNDX-6352) (DRUG).
Who is sponsoring clinical trial NCT07128381?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07128381 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis (MF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
ACTIVE NOT RECRUITING · Phase 1
-
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
RECRUITING
-
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
RECRUITING · Phase 2
-
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
ACTIVE NOT RECRUITING · Phase 3
-
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
COMPLETED · Phase 2
-
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.